Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THEO-260 in advanced ovarian cancer
NCT06618235Phase 2Recruiting
- Sponsor
- Theolytics
- Start
- Sep 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of THEO-260 in ovarian cancer, sponsored by Theolytics. Primary endpoints: Safety and tolerability of THEO-260 [Part A] at 28 days, Recommended Phase 2 dose (RP2D) for THEO-260 [Part A] at 2 years and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
THEO-260
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06618235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618235.